JP3187193B2 - Saponin-containing fiber - Google Patents
Saponin-containing fiberInfo
- Publication number
- JP3187193B2 JP3187193B2 JP04779593A JP4779593A JP3187193B2 JP 3187193 B2 JP3187193 B2 JP 3187193B2 JP 04779593 A JP04779593 A JP 04779593A JP 4779593 A JP4779593 A JP 4779593A JP 3187193 B2 JP3187193 B2 JP 3187193B2
- Authority
- JP
- Japan
- Prior art keywords
- fiber
- microcapsules
- saponin
- skin
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Chemical Or Physical Treatment Of Fibers (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Description
【０００１】[0001]
【産業上の利用分野】本発明は、肌荒れ防止、創傷治療
のほか、アセモ、ヒビ、アカギレ、火傷等の皮膚のトラ
ブルの改善、腫瘍、痔の治療等に優れた効果を示すサポ
ニン含有繊維に関するものである。さらに詳しくは、サ
ポニン入りマイクロカプセルを付着せしめて、耐久性の
あるサポニン効果を付与した繊維に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a saponin-containing fiber which has excellent effects in preventing skin roughening, treating wounds, improving skin troubles such as asemo, cracks, red pepper, burns, and treating tumors and hemorrhoids. Things. More specifically, the present invention relates to a fiber having a saponin effect with durability by attaching microcapsules containing saponin.
【０００２】[0002]
【従来の技術】従来より、ヘチマのつるや茎から得られ
る汁をヘチマ水と呼び、鎮咳去痰薬や利尿薬として用い
られてきた。また、化粧水としても潤肌の働きがあると
され、更に、東洋医学では、外傷、火傷、疥癬、腫瘍、
痔等の治療にも使用されてきた。このようなヘチマの消
炎、美肌効果をもたらす生理活性物質は、ルシオシド類
及びギンゼノシド類のサポニン配糖体であることが、近
年の研究効果から分かってきている［林輝明、フレグラ
ンスジャーナル、１０７、３７〜４３（１９９０）］。
また、特開昭６０―４８９９５号公報には、ヘチマサポ
ニンの製造方法も示されている。2. Description of the Related Art Hitherto, juice obtained from luffa vines and stems is called luffa water and has been used as an antitussive expectorant or diuretic. In addition, it is said that the lotion also works as a lotion, and in Oriental medicine, trauma, burns, scabies, tumors,
It has also been used to treat hemorrhoids and the like. It has been found from recent research effects that such physiologically active substances that bring out the anti-inflammatory and beautiful skin effects of luffa are saponin glycosides of luciosides and ginsenosides [Teruki Hayashi, Fragrance Journal, 107, 37]. 43 (1990)].
Further, Japanese Patent Application Laid-Open No. 60-48995 also discloses a method for producing hetimasaponin.
【０００３】[0003]
【発明が解決しようとする課題】従来、このようなヘチ
マサポニンは、もっぱら、液状で使用されてきたが、液
状であるために、使用時に流失、飛散し易く、ヘチマサ
ポニンが非常に高価なものであることもあって、流失や
飛散が起こらないよう効率的に使用できる用にすること
が大きな課題となっていた。また、一方では、乳幼児や
女性などの皮膚の弱い人が、下着によって肌荒れやかぶ
れを生じたり、あるいは乳児がおむつによってかぶれる
といったような問題も起こっている。本発明は、このよ
うな現状に鑑みなされたもので、ヘチマサポニンの流
失、飛散を防止して、効率的な使用を可能とし、更に
は、肌荒れや皮膚のかぶれを防止することのできる繊維
を提供することを目的とするものである。Heretofore, such luffemasaponins have been used exclusively in liquid form, but since they are in liquid form, they are easy to be washed away and scattered during use, and are extremely expensive. Because of this, it has been a major problem to use the device efficiently so that it will not be washed away or scattered. On the other hand, on the other hand, there are also problems such as the fact that people with weak skin, such as infants and women, suffer from rough skin and rash due to underwear, or babies are rashed with diapers. The present invention has been made in view of such a current situation, and prevents the loss and scattering of luffa saponin, enables efficient use, and furthermore, a fiber capable of preventing rough skin and skin rash. It is intended to provide.
【０００４】[0004]
【課題を解決するための手段】本発明者らは、上記目的
を達成すべく鋭意検討を重ねた結果、ヘチマサポニンを
マイクロカプセルに封入して繊維に付着させればよいこ
とを見出し、本発明に到達した。Means for Solving the Problems The inventors of the present invention have conducted intensive studies to achieve the above object, and as a result, have found that it is only necessary to encapsulate hememasaponin in microcapsules and attach it to the fiber. Reached.
【０００５】即ち、本発明は、 １． ヘチマサポニン入りマイクロカプセルを付着せし
めた繊維であって、該マイクロカプセルの付着量が、ヘ
キマサポニンの付着量として繊維重量に対して０．００
１重量％以上であるサポニン含有繊維。That is, the present invention provides: A fiber to which microcapsules containing luffemasaponin are adhered, wherein the amount of the microcapsules adhered to the fiber is 0.000.00
A saponin-containing fiber that is at least 1% by weight.
【０００６】２． マイクロカプセルとシリコン系樹脂
バインダーとを２：１〜１：５の割合で付着せしめた上
記１記載のサポニン含有繊維、である。[0006] 2. 2. The saponin-containing fiber according to 1 above, wherein the microcapsules and the silicone resin binder are attached at a ratio of 2: 1 to 1: 5.
【０００７】本発明で使用するヘチマサポニンは、ヘチ
マのつる、茎、葉から抽出されるエキスであり、その有
効成分は、ルシオシドＡ（１）、Ｂ（２）、Ｃ（３）、
Ｄ（４）、Ｅ（５）、Ｆ（６）、Ｇ（７）、Ｈ（８）、
Ｉ（９）とギンゼノシドＲｅ（１０）、Ｒｇ１（１１）
の１１種類のサポニン配糖体であると報告されている。The luffema saponin used in the present invention is an extract extracted from vine, stem and leaf of luffa, and its active ingredients are lucioside A (1), B (2), C (3),
D (4), E (5), F (6), G (7), H (8),
I (9) and ginsenoside Re (10), Rg1 (11)
Are reported to be 11 kinds of saponin glycosides.
【０００８】かかるヘチマサポニンを内包したマイクロ
カプセルを製造する方法自体は公知である。マイクロカ
プセルの壁剤は、適宜の摩擦によって壊れてヘチマサポ
ニンを放出するか、適宜の速度でヘチマサポニンを透過
徐放するものであれば特に限定されないが、有機ポリマ
ー例えばポリウレタン、尿素・ホルマリン樹脂等が好ま
しく用いられる。マイクロカプセルの大きさは、通常１
〜５０μｍ、好ましくは５〜２０μｍ程度のものを使用
し、壁剤の厚さは、０．３〜３μｍ好ましくは０．５〜
１．５μｍ程度とする。[0008] The method itself for producing such microcapsules encapsulating luffimasaponin is known. The wall material of the microcapsule is not particularly limited as long as it is broken by appropriate friction to release hemimasaponin, or is a substance capable of permeating sustained release of hemimasaponin at an appropriate speed. Is preferably used. The size of microcapsules is usually 1
の も の 50 μm, preferably about 5 to 20 μm, and the thickness of the wall material is 0.3 to 3 μm, preferably 0.5 to
It is about 1.5 μm.
【０００９】ヘチマサポニン入りマイクロカプセルを付
着させる繊維は、天然繊維、再生繊維、合成繊維のいず
れでもよく、繊維断面形状及び単糸繊度も任意であり、
かつその形態も、長繊維、短繊維、ウエブ、不織布（合
成紙）、織編物、縫製品等、その使用目的に応じて任意
である。The fibers to which the microcapsules containing luffa saponin are attached may be any of natural fibers, regenerated fibers, and synthetic fibers, and the fiber cross-sectional shape and single-fiber fineness are arbitrary.
The form is also arbitrary depending on the purpose of use, such as long fibers, short fibers, webs, non-woven fabrics (synthetic paper), woven and knitted goods, and sewn products.
【００１０】繊維に対するヘチマサポニンの付着量（付
着したマイクロカプセル中のトータルヘチマサポニン
量）は、０．００１重量％以上であることが必要であ
り、好ましくは０．０１重量％以上である。ヘチマサポ
ニンの付着量が０．００１重量％未満では、消炎、美肌
効果、肌荒れ、かぶれ防止効果が不十分となる。ヘチマ
サポニンの付着量は、多ければ多いほど、上記効果の持
続性が向上するが、あまり多すぎると、ヘチマサポニン
が高価であることから、コストが極めて高くなるため、
通常、２重量％以下とするのが好ましい。[0010] The amount of hemimasaponin adhering to the fiber (the total amount of hemimasaponin in the microcapsules attached) must be 0.001% by weight or more, and is preferably 0.01% by weight or more. If the amount of loofemasaponin is less than 0.001% by weight, the anti-inflammatory, beautiful skin effect, rough skin and rash prevention effects become insufficient. The greater the amount of loofetasaponin attached, the more the effect of the above-mentioned effect is improved.However, if the amount is too much, since loft of safflower is expensive, the cost becomes extremely high.
Usually, the content is preferably 2% by weight or less.
【００１１】本発明においては、上記マイクロカプセル
は、バインダーを併用して付着させるのが好ましい。こ
のようなバインダーは、水への分散性に優れ水で容易に
希釈できるものであることが好ましく、例えばポリビニ
ルアルコール系、シリコン系又はウレタン系の樹脂バイ
ンダーが用いられる。中でもオルガリノポリシロキサン
を主成分とし乳化剤で乳化したシリコン系エマルジョン
は、水の除去により硬化してゴム状皮膜を形成するた
め、耐久性のある接着効果を発揮するものである。In the present invention, the microcapsules are preferably attached together with a binder. It is preferable that such a binder is excellent in dispersibility in water and can be easily diluted with water. For example, a polyvinyl alcohol-based, silicon-based or urethane-based resin binder is used. Above all, a silicon-based emulsion containing an organopolysiloxane as a main component and emulsified with an emulsifier hardens by removing water to form a rubbery film, and thus exhibits a durable adhesive effect.
【００１２】なお、バインダーの量はマイクロカプセル
の量に対して０．５〜５倍、特に１〜２倍（重量比）の
範囲が好ましく、この範囲外ではマイクロカプセルの接
着効果が低下して耐久性が不充分になったり、繊維製品
の風合が硬化する場合があるので好ましくない。The amount of the binder is preferably 0.5 to 5 times, particularly 1 to 2 times (weight ratio) the amount of the microcapsules. It is not preferable because durability may be insufficient or the texture of the textile product may be hardened.
【００１３】マイクロカプセル及びバインダーを含む処
理液を繊維に付与する方法としては、浸漬法、ローラオ
イリング法、スプレー法等の任意の方法を用いることが
でき、繊維製造の任意の段階で付与することが可能であ
るが、ヘチマサポニンに高温の熱を加えることはあまり
好ましくないので、繊維に対するすべての熱処理が終了
した後で処理液を付与するのが好ましい。As a method for applying the treatment liquid containing the microcapsules and the binder to the fibers, any method such as a dipping method, a roller oiling method, and a spray method can be used. However, it is not preferable to apply a high-temperature heat to the luffemasaponin, so it is preferable to apply the treatment liquid after all the heat treatments on the fiber are completed.
【００１４】例えば、マイクロカプセルを付着させた合
成繊維からなる短繊維を製造する場合は、延伸、捲縮、
熱処理を施した切断直前のトウに対して、マイクロカプ
セルを含む処理液を、ヘチマサポニンの付着量が０．０
０１重量％以上となるように、ローラオイリング法で付
与する。For example, in the case of producing short fibers composed of synthetic fibers having microcapsules attached, stretching, crimping,
With respect to the tow immediately before cutting, which has been subjected to the heat treatment, the treatment liquid containing the microcapsules is applied with an adhesion amount of hemimasaponin of 0.0
It is applied by a roller oiling method so as to be at least 01% by weight.
【００１５】本発明の繊維を皮膚の炎症の治療、改善に
使用する場合は、ガーゼ、ウエブ、包帯などの形態で用
いることができる。また、合成繊維の肌着、おむつなど
が肌荒れや皮膚のかぶれの原因となる場合は、該合成繊
維にヘチマサポニンを付着させた本発明の繊維を用いれ
ば、肌あれ、かぶれを防止することができる。When the fiber of the present invention is used for treating and improving skin inflammation, it can be used in the form of gauze, web, bandage or the like. In addition, when underwear of synthetic fibers, diapers, etc. cause rough skin or rash on the skin, use of the fiber of the present invention in which hemimasaponin is attached to the synthetic fibers can prevent skin rash and rash. .
【００１６】[0016]
【実施例】以下、本発明を実施例により更に詳細に説明
するが、本発明は、これらの実施例に限定されるもので
はない。なお、以下の実施例及び比較例中の部及び％
は、特に断らない限り、重量部及び重量％を示す。EXAMPLES Hereinafter, the present invention will be described in more detail by way of examples, but the present invention is not limited to these examples. The parts and percentages in the following Examples and Comparative Examples
Represents parts by weight and% by weight unless otherwise specified.
【００１７】[0017]
【実施例１及び比較例１】３５℃のＯ―クロロフェノー
ルで測定した固有粘度が０．６４のポリエチレンテレフ
タレートを常法により溶融紡糸して得た未延伸トウを、
７５℃で４．５倍に延伸し、ついで捲縮加工後、１４０
℃で弛緩熱処理した。この、熱処理後のトウに、ヘチマ
サポニンと水を５：９５の割合で配合した液を内包する
マイクロカプセル（平均粒径８μｍ、膜厚１μｍ）１０
ｇ／Ｌ、エポキシ変成ジメチルポリシロキサンを主成分
とするシリコン系水性エマルジョン３０ｇ／Ｌの割合で
配合した処理液を、ローラーオイリング装置で付与し
た。Example 1 and Comparative Example 1 An undrawn tow obtained by melt-spinning polyethylene terephthalate having an intrinsic viscosity of 0.64 measured at 35 ° C. with O-chlorophenol by a conventional method,
The film was stretched 4.5 times at 75 ° C., and then crimped.
Relaxed heat treatment at ℃. A microcapsule (average particle size: 8 μm, film thickness: 1 μm) containing a liquid prepared by mixing hetimasaponin and water in a ratio of 5:95 to the tow after the heat treatment.
g / L, 30 g / L of a silicon-based aqueous emulsion containing epoxy-modified dimethylpolysiloxane as a main component was applied with a roller oiling device.
【００１８】処理液を付着させたトウを風乾した後、切
断して、繊度が６デニール、繊維長が５１ｍｍのポリエ
ステル短繊維を得た。このポリエステル短繊維のヘチマ
サポニン付着量は０．０１重量％であった。The tow to which the treatment liquid was attached was air-dried and cut to obtain polyester short fibers having a fineness of 6 denier and a fiber length of 51 mm. The amount of loofemasaponin attached to the polyester short fiber was 0.01% by weight.
【００１９】一方、比較例１では、上記処理液による処
理を行わず、その他の条件は実施例１と同じにして、ポ
リエステル繊維を得た。On the other hand, in Comparative Example 1, a polyester fiber was obtained in the same manner as in Example 1 except that the treatment with the treatment liquid was not performed.
【００２０】得られた各短繊維について、人体パネルで
肌荒れ改善効果試験を実施した。即ち、女性顔面のレプ
リカを採り、皮膚表面の皮紋の状態、角層の剥離状態か
ら、表１に示すように、肌荒れ評価を行い、評点が１，
２と判定された肌荒れ女性２５名を選び、顔面に、上記
各短繊維をウエブ化したものをそれぞれ貼付し、３日経
過後、表１のレプリカ法により肌の改善状態を観察、評
価した。結果は表２に示す通りであった。Each of the obtained short fibers was subjected to a skin roughness improving effect test on a human body panel. That is, a replica of the female face was taken, and from the state of the crest on the skin surface and the exfoliation state of the stratum corneum, the skin roughness was evaluated as shown in Table 1, and the score was 1,
Twenty-five women with rough skin determined to be 2 were selected, and each of the above short fibers made into a web was affixed to the face, and after 3 days, the improved state of the skin was observed and evaluated by the replica method shown in Table 1. The results were as shown in Table 2.
【００２１】[0021]
【表１】 [Table 1]
【００２２】[0022]
【表２】 [Table 2]
【００２３】ヘチマサポニン入りマイクロカプセルを付
着した短繊維（実施例１）では、肌荒れ改善効果が認め
られたが、ヘチマサポニン入りマイクロカプセルを付着
しない短繊維（比較例１）では、肌荒れ改善効果は認め
られなかった。The short fibers to which microcapsules containing luffasaponin were adhered (Example 1) exhibited an effect of improving skin roughness, whereas the short fibers to which no microcapsules containing leptima saponin were adhered (Comparative Example 1) showed an effect of improving rough skin. I was not able to admit.
【００２４】[0024]
【発明の効果】本発明によれば、ヘチマサポニンの流
失、飛散を防止し、高価なヘチマサポニンを消炎、美肌
のために効率的に使用することができ、更には、合成繊
維などによる肌荒れや皮膚のかぶれを防止することがで
きる。According to the present invention, efemasaponin can be prevented from being washed away and scattered, and expensive efemasaponin can be efficiently used for extinguishing and beautiful skin. It can prevent skin irritation.
───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 昭60−48995（ＪＰ，Ａ) (58)調査した分野(Int.Cl.7，ＤＢ名) D06M 13/00 - 15/72 D06M 23/12 A61K 31/70 A61K 35/78 A61L 15/00 - 15/07 ────────────────────────────────────────────────── (5) References JP-A-60-48995 (JP, A) (58) Fields investigated (Int. Cl. 7 , DB name) D06M 13/00-15/72 D06M 23 / 12 A61K 31/70 A61K 35/78 A61L 15/00-15/07
Claims (2)
付着せしめた繊維であって、該マイクロカプセルの付着
量が、ヘキマサポニンの付着量として繊維重量に対して
０．００１重量％以上であるサポニン含有繊維。1. A fiber to which microcapsules containing hemimasaponin are adhered, wherein the amount of the microcapsules is 0.001% by weight or more based on the weight of the fiber as the amount of hemimasaponin adhered.
ンダーとを２：１〜１：５の割合で付着せしめた請求項
１記載のサポニン含有繊維。2. The saponin-containing fiber according to claim 1, wherein the microcapsules and the silicone resin binder are adhered at a ratio of 2: 1 to 1: 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP04779593A JP3187193B2 (en) | 1993-03-09 | 1993-03-09 | Saponin-containing fiber |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP04779593A JP3187193B2 (en) | 1993-03-09 | 1993-03-09 | Saponin-containing fiber |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06264367A JPH06264367A (en) | 1994-09-20 |
| JP3187193B2 true JP3187193B2 (en) | 2001-07-11 |
Family
ID=12785311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP04779593A Expired - Fee Related JP3187193B2 (en) | 1993-03-09 | 1993-03-09 | Saponin-containing fiber |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3187193B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7388223B2 (en) | 2003-05-28 | 2008-06-17 | Samsung Sdi Co., Ltd. | Flat panel display device and method of fabricating the same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101141662B1 (en) * | 2010-03-03 | 2012-05-04 | 주식회사 화성닛트 | Textile containing red ginseng ingredient and socks thereby |
-
1993
- 1993-03-09 JP JP04779593A patent/JP3187193B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7388223B2 (en) | 2003-05-28 | 2008-06-17 | Samsung Sdi Co., Ltd. | Flat panel display device and method of fabricating the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06264367A (en) | 1994-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6506394B1 (en) | Delivery of a botanical extract to a treated substrate for transfer to skin | |
| EP2394617B1 (en) | Layer-like perforated biomatrices | |
| DE60224718T3 (en) | SKIN CARE SYSTEM FOR USERS OF ABSORBENT ARTICLES | |
| EP2270082B1 (en) | Alginate-containing porous shaped mouldings | |
| US6503524B1 (en) | Delivery of a skin health benefit agent to a treated substrate for transfer to skin | |
| JPH021408A (en) | Medicinal cleansing pad | |
| US8784875B2 (en) | Collagen for use in the treatment of skin diseases | |
| CN1348387A (en) | Skin-friendly absorbent articles and compositions | |
| WO2001000155A1 (en) | Silk protein treatment composition and treated substrate for transfer to skin | |
| JP2008150396A (en) | System for delivering cosmetic and pharmaceuticals | |
| JP2006519263A (en) | Invisible patch for controlled delivery of ingredients with cosmetic, dermatological and pharmaceutical activity to the skin | |
| DE102007016684A1 (en) | Biodegradable multi-layer system | |
| US6500443B1 (en) | Delivery of a sacrificial substrate to inhibit protease permeation into skin | |
| KR20020030264A (en) | Skin-Friendly Absorbent Articles and Compositions | |
| JP3187193B2 (en) | Saponin-containing fiber | |
| Gürtler et al. | Electrospun fibers for the treatment of skin diseases | |
| WO2001000156A1 (en) | Delivery of a skin health benefit agent to a treated substrate for transfer to skin | |
| JP3187189B2 (en) | Saponin-containing fiber and method for producing the same | |
| CN113967175A (en) | Sheet-type mask gel composition, mask sheet comprising same and mask sheet preparation method | |
| JPH07330575A (en) | Sheet-like pack | |
| DE69720072T2 (en) | FABRIC TISSUE WITH EXTENDED THERAPEUTIC EFFECT | |
| JP2004316017A (en) | Fiber structure | |
| JP4548971B2 (en) | Fiber containing skin care agent | |
| AT145334B (en) | Compress. | |
| DE202022106557U1 (en) | Mesh Face Mask |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080511 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090511 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090511 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100511 Year of fee payment: 9 |
|
| LAPS | Cancellation because of no payment of annual fees |